ZYME | Ticker Profile - Titan Protect

ZYME

Zymeworks Inc.

Healthcare · Biotechnology · NMS

$24.04

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.8B

Total market value of the company

Trailing P/E

N/A

Forward P/E

48.07

Based on estimated future earnings — lower means cheaper

Rev Growth

-91.1%

Year-over-year revenue change

Profit Margin

-126.3%

How much profit the company keeps from each dollar of revenue

ROE

-42.0%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$40.00

+66% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 13 analysts covering this stock

About Zymeworks Inc.

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

https://www.zymeworks.com

Country: United States Employees: 243 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

1.326

Excellent risk-adjusted returns

Kelly Fraction

0.1072

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

1.616

Returns exceed worst-case losses — strong risk profile

Annual Return

73.9%

Historical annualised return based on price data

Max Drawdown

-45.8%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.19

Moves slightly more than the broader market

52W High

$29.75

19% below the year high

52W Low

$11.02

118% above the year low

Avg Volume

680,822

Average daily shares traded — higher means easier to buy and sell

Short Ratio

7.1

Days it would take all short sellers to cover — higher means more crowded

Short % Float

9.1%

Moderate short interest

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.37

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

10.42

Heavy leverage — higher financial risk if revenues decline

Current Ratio

10.82

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

10.36

Like current ratio but excludes inventory — stricter test

Gross Margin

-67.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-1,956.7%

Profit from core operations before interest and tax

Free Cash Flow

$-45,503,000

Negative — the business is spending more than it generates

Revenue (TTM)

$81M

Total revenue over the last 12 months

Net Income

$-102,656,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$58.00

Target Median

$40.00

Target Low

$31.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go